EyeYon Medical
- Industry
- Medical Devices
- Founded Year
- 2010
- Headquarters
- Ness Ziona, Israel
- Employee Count
- 50
Key People
- Nahum Ferera - CEO
- Dr. Ofer Daphna - Co-Founder & Chief Medical Officer
- Dr. Yair Morad - Co-Founder & Chief Technology Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in medical technology and ophthalmology.
The co-founders have significant experience in the medical field, particularly in ophthalmology, which is crucial for developing and commercializing ophthalmic devices.
- Clinical Need
-
Aspect: Very Strong
Summary: EyeYon Medical addresses significant unmet needs in corneal health with innovative solutions.
Corneal edema and the need for effective therapeutic contact lenses represent substantial clinical challenges, and EyeYon's products offer novel solutions to these issues.
- Competition
-
Aspect: First mover
Summary: EyeYon Medical is pioneering in the development of synthetic implants for corneal edema.
While first-mover advantage allows for market leadership, it also requires significant resources for market development and carries the risk of competitors entering the space with improved offerings.
- Technical Challenge
-
Aspect: Complex
Summary: Developing synthetic corneal implants involves significant technical complexities.
The creation of biocompatible, durable, and effective synthetic implants for the eye requires overcoming substantial material science and biomedical engineering hurdles.
- Patent
-
Aspect: Strong
Summary: EyeYon Medical holds strong patents for its innovative products.
Patents provide legal protection for the company's innovations, preventing competitors from replicating their technology and allowing for potential licensing opportunities.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
Investment from established venture capital firms indicates confidence in the company's potential and provides the necessary capital for product development and commercialization.
- Regulatory
-
Aspect: Pivotal Trial
Summary: EyeYon Medical's products are undergoing pivotal clinical trials.
Pivotal trials are essential for demonstrating safety and efficacy to regulatory bodies, and their outcomes will significantly impact the company's ability to commercialize its products.
Opportunity Rollup
- Odds of Success
- 3.1
- Peak Market Share
- 3.7
- Segment CAGR
- 4.3%
- Market Segment
- Ophthalmic Devices
- Market Sub Segment
- Corneal Implants and Therapeutic Contact Lenses
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.19 |
| 2 | 0.56 |
| 3 | 1.30 |
| 4 | 2.59 |
| 5 | 3.70 |
Key Takeaway
EyeYon Medical is well-positioned in the ophthalmic devices market with innovative products addressing significant clinical needs, supported by a strong team and investor backing.